79996-99-9

Basic information

• Product Name: 1-BROMO-4-(BROMOMETHYL)NAPHTHALENE
• Synonyms: 1-BROMO-4-(BROMOMETHYL)NAPHTHALENE
• CAS NO: 79996-99-9
• Molecular Formula: C₁₁H₈Br₂
• Molecular Weight: 299.99
• Product Categories: blocks;Bromides
• Mol File: 79996-99-9.mol
• Article Data: 22

Chemical Properties

• Melting Point: 102-105℃ (hexane )
• Boiling Point: 195-210 °C
• Appearance: /
• Density: 1.772±0.06 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 1-BROMO-4-(BROMOMETHYL)NAPHTHALENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BROMO-4-(BROMOMETHYL)NAPHTHALENE(79996-99-9)
• EPA Substance Registry System: 1-BROMO-4-(BROMOMETHYL)NAPHTHALENE(79996-99-9)

Safety Data

• Hazardous Substances Data: 79996-99-9(Hazardous Substances Data)

Usage

General Description

1-Bromo-4-(bromomethyl)naphthalene is a chemical compound with the molecular formula C11H8Br2. It is a derivative of naphthalene and is commonly used as a brominating agent in organic synthesis. 1-BROMO-4-(BROMOMETHYL)NAPHTHALENE is a white to light yellow solid with a strong, pungent odor. It is soluble in organic solvents such as acetone, ether, and chloroform, but insoluble in water. 1-Bromo-4-(bromomethyl)naphthalene is also known for its use in the synthesis of various pharmaceuticals and agrochemicals, as well as in the production of fluorescent dyes and other specialty chemicals. It is important to handle this compound with care, as it is toxic if swallowed, inhaled, or absorbed through the skin, and it may cause skin and eye irritation.

Upstream product

• 75-15-0 carbon disulfide 
• 7726-95-6 bromine 
• 90-12-0 1-Methylnaphthalene 
• 46258-62-2 1-(4-bromonaphthalen-1-yl)ethanone 
• 16650-55-8 4-bromonaphthalene-1-carboxylic acid 
• 90-11-9 1-Bromonaphthalene 
• 288372-59-8 1-allyldimethylsilyl-4-bromonaphthalene 
• 83-53-4 1,4-dibromonaphthalene 
• 288372-60-1 1-allyldimethylsilyl-4-naphthalenemethanol 
• 6627-78-7 1-bromo-4-methylnaphthalene 
• 56052-26-7 (4-bromonaphthalen-1-yl)methanol 
• 50-00-0 formaldehyd 
• 3163-27-7 2-(bromomethyl)naphthalene 

Downstream Products

• 50672-84-9 4-bromo-1-naphthaldehyde 
• 35615-97-5 4-bromo-naphthalene-1-carboxylic acid methyl ester 
• 1234382-25-2 5-(3,5-dichloro-phenyl)-5-trifluoromethyl-3-(4-trimethylsilanylethynyl-naphthalen-1-yl)-4,5-dihydro-isoxazole 
• 1234381-54-4 5-(3,5-dichloro-phenyl)-3-{4-[1-(2,2,2-trifluoro-ethyl)-1H-pyrazol-4-yl]-naphthalen-1-yl}-5-trifluoromethyl-4,5-dihydro-isoxazole 
• 1234381-72-6 2-(4-{4-[5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-naphthalen-1-yl}-[1,2,3]triazol-1-ylmethyl)-pyridine 
• 1234381-46-4 4-{4-[5-(3,5-dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-naphthalen-1-yl}-pyrazole-1-carboxylic acid tert-butyl ester 
• 1234381-53-3 5-(3,5-dichloro-phenyl)-3-[4-(1H-pyrazol-4-yl)-naphthalen-1-yl]-5-trifluoromethyl-4,5-dihydro-isoxazole 
• 1234382-26-3 5-(3,5-dichloro-phenyl)-3-(4-ethynyl-naphthalen-1-yl)-5-trifluoromethyl-4,5-dihydro-isoxazole 
• 943847-23-2 3-(4-bromo-1-naphthalenyl)-5-(3,5-dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)isoxazole 
• 92616-49-4 4-bromonaphthalene-1-carbonitrile 

Relevant articles and documents

Enantioselective approach to both enantiomers of helical bisquinones

-

Discovery of Novel Bicyclic Imidazolopyridine-Containing Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Improved Efficacy and Favorable Druggability

Lesinurad is a uricosuric agent for the treatment of hyperuricemia associated with gout, which was found lacking in efficacy and safety. Here, scaffold hopping and molecular hybridization were exploited to modify all the structural components of lesinurad, and 36 novel compounds bearing bicyclic imidazolopyridine core were obtained. In a mouse model of acute hyperuricemia, 29 compounds demonstrated increased serum uric acid (SUA)-reducing activity; SUA was treated with 12, 23, and 29 about fourfold lower compared with that of lesinurad. Moreover, 23 exhibited stronger URAT1 inhibition activity (IC50 = 1.36 μM) than lesinurad (IC50 = 5.54 μM). Additionally, 23 showed favorable safety profiles, and no obvious acute toxicity was observed in Kunming mice under a single dose of 1000 mg·kg-1. 23 also achieved excellent pharmacokinetic properties with the oral bioavailability of 59.3%. Overall, all the results indicated that 23 is a promising drug candidate in the treatment of hyperuricemia and gout.

CRYSTAL FORM OF URATE TRANSPORTER 1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF

The present invention provides a crystal form of urate transporter 1 inhibitor and a preparation method and use thereof. The crystal form is characterized by a stable state of appearance and a capability of further improving the purity and storage stability of the compound, etc., and suitable as a pharmaceutical raw material.

METHOD FOR PREPARING URATE TRANSPORTER 1 INHIBITOR

Provided is a method for preparing a URAT1 inhibitor, 2-((5-bromo-4-((4-bromonaphthalen-1-yl)methyl)-4H-1,2,4-triazol-3-yl)thio) acetic acid represented by the following formula ZXS-BR, the reaction equation of which being shown as follows. Compared with the prior art, the preparation method provided by the present application is of low cost, ease of handling, ease of quality control, and applicable to industrialization.